Medical Care Toranomon, Tokyo, Japan Aim: Although the effects of psychotropics on driving ability have received much attention, little research is available on driving performance of stable outpatients with depression undergoing realworld treatment. This observational study investigated driving performance, cognitive functions, and depressive symptomatology of partly remitted outpatients with depression under daily-practice psychopharmacologic treatment.
patients in whom depression has remitted. 9, 10 In daily life functioning, automobile driving is fundamental to the autonomy of many people worldwide, including patients with major depressive disorder (MDD). Many psychiatric patients have difficulties in psychomotor functions relevant for driving. 11, 12 Cognitive symptoms, the pathology itself, and the medication used may affect driving performance. 9, 10, 13, 14 Although long-term medication is crucial to preventing recurrence and relapse in patients with depression, 15 all package inserts of psychotropics in Japan, except those for paroxetine, sertraline, escitalopram, duloxetine, milnacipran, and venlafaxine, prohibit patients from driving a car regularly and continually. This ban on driving might interfere with patients' social lives, despite the lack of sufficient evidence to support such a ban.
Some epidemiologic studies have shown that depression, defined retrospectively by questionnaires, is associated with increased traffic accidents, 16, 17 but other research has shown no association. 18 On the other hand, recent epidemiologic studies regarding antidepressants and traffic accidents showed that there were minor increased risks for traffic accidents associated with the use of any kind of antidepressant, [19] [20] [21] [22] especially after the initiation or change of antidepressant treatment. 21 Early studies also showed increased risks for traffic accidents associated with tricyclic antidepressant use in older patients. 23, 24 Epidemiologic studies concerning depression and traffic accidents remain inconclusive because there are unavoidable problems with confounding factors and diagnostic accuracy.
Experimental studies using on-road or simulated driving tests or neurocognitive batteries related to driving fitness can complement the findings of epidemiologic studies. Several experimental studies in healthy participants have shown that acute administration of sedative antidepressants impairs driving performance compared with non-sedative antidepressants. [25] [26] [27] Untreated patients with MDD showed a decline in driving performance compared with healthy controls (HC), 28 and the therapeutic effects of antidepressants on driving performance have been observed in previous studies. In fact, antidepressants, including the sedative antidepressant, mirtazapine, have been shown to significantly improve driving performance of patients with depression. [29] [30] [31] As with epidemiologic studies, in experimental studies, the driving performance of patients with depression treated with antidepressants has differed due to different methods of evaluation. Although changes in driving performance may be attributed to the class of antidepressant 12 or residual depressive symptoms 32 in a controlled setting, little research is available on driving performance in patients with depression during treatment, especially while receiving real-world pharmacologic treatment, which often involves multiple agents, rather than antidepressant monotherapy.
Overall, there is relatively little literature in the area of driving with mental health conditions, 33 and real-world data on driving performance of patients with MDD remain unknown. In the present study, we examined whether the driving performance of outpatients with depression undergoing real-world treatment was inferior to that of HC.
METHODS Participants
Seventy stable outpatients with depression (64 men and six women) aged 24-57 years (mean AE SD, 41.5 AE 7.1 years) were enrolled from September 2012 through July 2015 in Sapporo Ekimae Clinic, Sapporo, Medical Care Toranomon, Tokyo, NTT Medical Center, Tokyo, Okehazama Hospital, Aichi, and Nagoya University Hospital, Nagoya, using an advertisement for this study. All patients had a diagnosis of MDD established by the DSM-IV 34 criteria. In addition, patients met the criteria for depression based on the Structured Clinical Interview for DSM-IV (SCID). 35 The dosage and choice of pharmacotherapy were selected on an individual clinical basis by the treating psychiatrist. No medications were changed within 4 weeks preceding participation. In keeping with the real-world clinical setting, psychotropic drugs were not controlled in this study. Participants with a history of neurologic illness, substance dependence, or mental retardation were excluded.
In addition, 67 sex-and age-matched healthy volunteers (62 men and five women) aged 23-56 years (mean AE SD, 40.9 AE 6.9 years) were recruited using an advertisement for this study. Healthy participants were free from any psychiatric disorders established by the SCID and were not taking any psychotropic drugs. All participants had a valid driving license for at least 3 years and had been driving a car daily. The Nagoya University Graduate School of Medicine and Nagoya University Hospital ethics review committee approved the study, and written informed consent was obtained from each volunteer before participation. All participants received substantial training to operate the driving simulator until they reached the plateau level in training both to understand the test instructions and to achieve an operational feeling for simulator driving, which is different from actual driving.
Assessments Driving performance
We used a driving simulator (Toyota Central R&D Labs, Inc., Nagakute, Japan) to examine three driving skills that appeared to be associated with traffic accidents, including frequent rear-end collisions. 36 This simulator software was run on a personal computer equipped with a steering wheel, gas, and brake pedal system. Images were projected onto a 1620 × 1220 mm screen via an LCD projector. The same simulator has been used in previous studies 26, 37 ; details of the simulator configuration and driving tasks have been described previously. 26 The road-tracking test used in the present study was based on a previously developed test. 38, 39 A gently winding and non-straight, two-lane road with no other traffic continued throughout the test. Subjects were instructed to drive at a constant speed of 100 km/h and stabilize their vehicles at the center of the left lane. The standard deviation of the lateral position (SDLP, in cm), which indicates weaving, was considered as the performance measure for the road-tracking test. The car-following test included a straight two-lane road with the only other traffic being a single preceding car. As the preceding car accelerated (to 60 km/h) or decelerated (to 40 km/ h), the subject was required to maintain a constant distance between cars (targeted distance of 5 m) in the context of driving on crowded urban roads. This performance was measured as the coefficient of variation (CV) obtained by dividing the SD of the carfollowing distance (m) between the cars by the mean value. 37 Therefore, a smaller value of distance CV (DCV) would indicate a better performance. The harsh-braking test included a straight two-lane road with no traffic, but with humanoid models on either side of the left lane. The subject was required to maintain a constant speed of 50 km/h and to use harsh braking to avoid crashing into the humanoid models that randomly ran into the road. The test consisted of seven braking trials, and the mean brake reaction time (BRT, in ms) was considered the performance measure. Each test was recorded every 20 ms and lasted for 5 min.
Cognitive function
The Continuous Performance Test Identical Pairs version (CPT-IP) 40 was used to measure sustained attention. A series of four-digit stimuli were presented for 50 ms, with an interstimulus interval (ISI) of 950 ms. Each completed task consisted of 150 trials, of which 30 were target trials requiring a response. In this test, performance was measured by the signal detection index d-prime (d 0 ), which is a measure of discriminability computed from 'hits' and 'false alarms.' A modified computerized version of the Wisconsin Card Sorting Test 41, 42 was administered to measure executive function, and the test lasted until such time as 48 cards were sorted. Performance was measured by the following indices: category achievement (CA), perseverative errors of Nelson (PEN), and difficulty of maintaining set. The Trail-Making Test parts A and B were used to measure psychomotor speed, attention, visual scanning ability, and executive functioning. 43 In part A, subjects were instructed to connect an ascending series of circles containing numbers as quickly as possible. In part B, subjects were instructed to alternate between numbers and letters. The performance measures in these tests were the time required to complete each condition.
Symptom assessment
The severity of depressive symptoms was rated by the Structured Interview Guide for the 17-item Hamilton Depression Rating Scale (HAMD) 44 and the Beck Depression Inventory-II (BDI-II). 45 Social functioning in depression was also evaluated by the Social Adaptation Self-Evaluation Scale (SASS). 46 Because sleepiness can affect driving performance, 47 the Stanford Sleepiness Scale (SSS), a 7-point, selfreporting measure of alertness with proven sensitivity, was evaluated. 48 All patients were administered these assessments and healthy participants were administered the BDI-II, SASS, and SSS.
Statistical analysis
This study has more than 80% power to detect a between-group difference of 0.5 SD, which corresponds to a medium effect size difference in Cohen's criteria. In analyses, variables were compared using parametric tests or nonparametric tests according to the distribution. Variables of age, driving experience, BRT, SASS, and d' were analyzed using the Student's t-test, and other variables were analyzed using the Mann-Whitney U-test. Statistical analyses were performed using SPSS version 23 (IBM SPSS Japan, Tokyo, Japan). All tests were two-tailed, and the alpha was set at 0.05.
RESULTS

Demographic, clinical, and pharmacologic variables
Two patients could not follow the instructions for the driving tests due to lack of understanding and were removed from the analysis. In terms of pharmacologic treatment, prescriptions of two patients were unknown and one patient used no medication, so we removed them from the analysis. Consequently, 65 of the 70 patients were suitable for the statistical analysis. Table 1 shows the general characteristics of participants. There were significant differences in frequency of driving and driving mileage between patients and HC. Most patients reached remission in this study. Many patients received coadministration of antidepressants, benzodiazepines, and antipsychotics.
Driving performance
Results of the driving tests are shown in Table 2 . None of the participants suffered from simulator sickness. Although there was no significant difference in the three driving tasks, the distribution of DCV seemed to be different between patients with depression and HC, unlike that of the SDLP and BRT. The distribution of DCV was skewed in patients with depression and the proportion of patients beyond DCV = 100, which is the third quartile plus half again the interquartile range of DCV, in HC was about 30% (DCV ≥ 100, n = 20, 32%; DCV < 100, n = 42, 68%). Therefore, in a post hoc analysis for DCV, we conducted an analysis of covariance (ANCOVA) with age, education, driving experience, and Log annual mileage (F = 0.63, d.f. = 1,105, P = 0.63). In this model, there was no significant relation between Log DCV and age (B = 0.014, SE = 0.013, β = 0.28, P = 0.29), education (B = 0.042, SE = 0.022, β = 0.19, P = 0.058), or driving experience (B = −0.011, SE = 0.013, β = −0.22, P = 0.41), whereas annual mileage significantly and inversely 
Cognitive function
Results of the cognitive tests are also shown in Table 2 . Some HC lacked data for the cognitive tests because of technical failure and unadministered test. There were no significant differences in cognitive tests between the groups except for the score for the Wisconsin Card Sorting Test -difficulty of maintaining set (P = 0.009).
Relation between driving performance and Symptom Assessment Scale
Results of the relation between driving performance and the Symptom Assessment Scale are shown in Table 3 . We analyzed driving performance by remission defined by HAMD and BDI-II. 49 The patients were divided into two groups based on HAMD 7/8 (HAMD ≥ 8, n = 14, 22% and HAMD ≤ 7, n = 50, 78%), and on BDI-II = 13/14 (BDI-II ≥ 14, n = 24, 37.5% and BDI-II ≤ 13, n = 40, 62.5%). No significant difference was found in the three driving performances between the two groups in relation to the HAMD and BDI-II. We also analyzed driving performance by social function measured by SASS. The optimal cut-off point of the Japanese version of the SASS (SASS-J) is 25/26. 50 Patients with depression were divided into two groups based on the SASS-J (SASS-J ≤ 25, n = 13, 20% and SASS-J ≥ 26, n = 51, 80%). There were significant differences in SDLP (P = 0.049) and DCV (P = 0.017) between the groups. No significant difference was found in BRT between the groups.
DISCUSSION
From our data we can conclude that partly remitted depressive patients under steady-state pharmacologic treatment do not differ from HC with respect to driving performance, which might indicate that for these patients, driving might not be as unsafe as previously thought. However, more research is needed to make firm statements about fitness to drive in outpatients with depression receiving pharmacotherapy. Social function measured by the SASS seems to be involved in driving performance compared to the severity of depressive symptoms in those populations. When evaluating the driving fitness of patients with depression, it is necessary to consider various factors, including social function, comprehensively.
Driving performance in patients with depression
Previous studies have shown that patients with depression receiving long-term antidepressants had impairments in driving performance, 12, 32 which is different from the current study. Wingen et al. showed that patients with depression receiving nonsedative antidepressant monotherapy had impairment in road-tracking performance on the road-driving test compared with HC. Many patients in that study were on pre-remission, and scores for both the HAMD and BDI were greater than those of patients in the present study. In addition, the sample size in their study was smaller than that of the present study. Brunnauer et al. 12 showed that many inpatients with depression receiving various antidepressants as monotherapy had driving impairment as measured by computerized cognitive batteries defined by a German guideline. Many patients did not achieve remission, and HAMD scores were greater than those of patients in the present study. Depression severity, sample size, and methodology of driving evaluation may explain the different results. On the other hand, about 30% of patients were beyond the distribution of HC in the car-following test in the present study, despite no statistical difference between patients and HC. It suggested that driving performance of patients with depression may not be exactly the same as that of HC, as was shown in previous studies. 12, 32 Further research is needed to confirm driving performance of patients with depression under long-term pharmacologic treatment.
32
Factors affecting driving performance in patients with depression
In our driving simulator, annual mileage significantly and inversely affected car-following performance through ANCOVA. This means that car-following performance is better when the annual mileage is higher. Although there is no evidence that annual mileage is related to driving performance, there is a possibility of association between annual mileage and car-following performance as follows. The car-following test requires participants to pay continuous attention to the preceding car rather than to other driving tasks. Drivers' experience has been shown to be associated with driving performance involving visual attention. 51 Because annual mileage is thought to represent practical driving experience, annual mileage may have had an effect on car-following performance in this study.
Although evaluation of fitness for driving in patients with depression is difficult in clinical practice, social function may have provided additional information for estimating driving performance of patients with depression in this study. Social function measured by SASS had an influence on driving performance compared to remission of depression measured by the HAMD and BDI. Treatment response is measured by improvement in depressive symptoms, but functional improvement often lags behind symptomatic improvement. Functional impairment contributes to significant disability in MDD.
52 SASS might also have appropriately recognized residual depressive symptoms related to driving impairment in past studies. 12, 32 Favorable social function is thought of as not the only factor but as one of the factors determining driving ability. Although the SASS score suitable for determining Relation between pharmacotherapy and driving performance
Pharmacologic treatment in this study was not controlled in the context of the real-world clinical setting, and the psychotropics used varied from patient to patient. Therefore, driving performance classified in terms of psychotropics used, such as antidepressants, was not investigated. Driving performance of partly remitted depressive patients under steadystate pharmacologic treatment did not differ from that of HC. This finding is different from earlier results that driving fitness is affected differently by different types of antidepressants. 12 On the other hand, a recent systematic review showed that pharmacotherapy, including augmentation therapy with antipsychotics, may reduce cognitive impairment in depressed patients.
14 Antidepressants can improve driving performance in untreated patients with depression 29, 30 and administration of psychotropics, including antidepressants and hypnotics, can decrease a drug's influence on driving performance. 25 ,53 Because we did not examine driving performance over time, further research is needed regarding the confounding of depression and pharmacotherapy. At a minimum, the above findings suggest that Japanese package inserts that prohibit patients receiving psychotropics from driving a car on a continuing basis do not seem to represent evidence-based information.
Limitations
The present study has several limitations. First, most participants were restricted to remitted patients with MDD. Thus, these results may not be generalized to all patient populations with depression. Second, the study did not include a sufficient number of female patients or older adult patients, even though these two groups have a high prevalence of MDD in the general population. Third, HC had a high education level and annual mileage level. Nevertheless, there were no significant differences in the driving tests between patients with depression and HC. Fourth, pharmacologic treatments and adherence to treatment in patients with depression were not controlled, and analysis based on psychotropics used, such as antidepressants, was not conducted. However, the present findings may still be representative of a real-world clinical setting. [54] [55] [56] Fifth, the validity and sensitivity of the driving simulator need to be considered. The values of our driving simulator in this study cannot be compared with an actual driving test, simulated driving tests, or computerized cognitive batteries used in past studies. However, our past results using the same simulator in terms of pharmacologic effect in HC are roughly consistent with other studies. 25, 57, 58 Further investigations are needed for the assessment of fitness to drive with a combination of various measurements.
Conclusions
We conclude that partly remitted depressive patients under steady-state pharmacologic treatment do not differ from HC with respect to driving performance, which seems to be more affected by psychosocial functioning than by pharmacologic agents. This, however, should be investigated systematically in an off/on study.
